New Hire Announcement – Chief Operations Officer

Paradromics hires Chief Operations Officer, James Burrows

Paradromics is proud to announce the addition of James Burrows as the company’s Chief Operating Officer. James’s extensive experience in the medical device field will add critical expertise to the already impressive Paradromics team. James will be a key member of the executive team, working side by side with CEO Matt Angle on Corporate Strategy and Execution. His responsibilities will include Operations, Quality, Regulatory and Clinical.

James Burrows joins Paradromics with more than 25 years of experience as a global leader in the medical device industry. Recently, he was the Global Vice President of Operations, Supply Chain, Regulatory and Clinical for Zimmer Biomet Spine. Prior to Zimmer Biomet he served as Chief Operating Officer for LDR Holding where he was an executive leader for the organization. During his more than 10 years with LDR, the company established a U.S. entity, and conducted two concurrent IDE clinical trials, bringing a novel new Class III medical device to the market. The introduction of LDRs Class III artificial disc resulted in one of the fastest growing spine companies following the successful IPO and ultimate one billion dollar acquisition by Zimmer-Biomet.

“Through our comprehensive recruitment efforts, we were impressed with James’ knowledge of the medical device industry,” said Matt Angle, CEO. “We know both his strong background as a skilled and strategic operator and commercial focus will enable him to lead Paradromics to successful commercialization of our brain computer interface technology.

Mr. Burrows stated, “I am excited to join Paradromics as we bring this breakthrough medical technology to patients in great need of treatment options. I have been impressed with the team’s expertise as well as their focus and dedication to the people who will benefit from this revolutionary technology. I have dedicated my career to bringing products to the market that improve the quality of life for patients. The process for bringing Paradromics novel brain computer interface device will be similar to other Class II and Class III devices that require clinical evidence, but is expected to be much faster due to endpoints required to demonstrate efficacy.”

If you would like more information, please email: